Back HIV/AIDS

HIV / AIDS

Maraviroc Dose May Be Too Low for Many African-American People with HIV

A standard dose of the CCR5 antagonist maraviroc (Selzentry) may not be effective for many black people with HIV due to a genetic variation which increases production of a cytochrome P450 protein that speeds up processing of the drug, according to a study published in the August 12 advance edition of Drug Metabolism and Disposition.

alt

AIDS 2014: Most Gay Men Who Don’t Use Condoms Attempt to Reduce HIV Risk

Three-quarters of Australian gay and bisexual men who report unprotected anal intercourse with casual male partners say that they often or always employ some sort of risk reduction strategy with those partners, according to a report at the 20th International AIDS Conference in Melbourne. Many men attempt to select partners who they believe have the same HIV status as themselves (serosorting), a significant proportion use condoms most but not all of the time, and smaller numbers practice "strategic positioning" or withdrawal before ejaculation.

alt

Counseling Helps Improve PrEP Adherence Among Serodiscordant Couples

Cognitive-behavioral counseling sessions significantly increased the likelihood of consistently taking pills among participants with faltering adherence in an African trial of Truvada pre-exposure prophylaxis (PrEP) for serodiscordant (mixed HIV status) heterosexual couples, according to a report in the August 15 Journal of Acquired Immune Deficiency Syndromes.

alt

Mississippi Baby and Other Relapsers Hold Lessons for HIV Cure

Despite the disappointment felt by many, the return of detectable HIV in the Mississippi Baby and 2 patients who received bone marrow transplants are of "enormous scientific importance" and indicate that addressing the latent viral reservoir is the major challenge in achieving a cure or long-term remission, according to an editorial in the August 29 edition of Science.

alt

Hepatitis C Infections Fall after Harm Reduction Scale-up in Scotland

Hepatitis C virus (HCV) incidence among people who inject drugs declined rapidly after national scale-up of harm reduction interventions such as syringe exchange in Scotland, according to a report published in the August 11 edition of PLoS ONE. Changes in HCV prevalence, however, are lagging behind.

alt

HIV May Damage Gut and Trigger Inflammation Within Days of Infection

An HIV-like simian virus disrupted the gut lining within 3 days after infection, due to an inflammatory response initiated by Paneth cells that produce interleukin 1-beta (IL-1β), according to a report in the August 28 issue of PLoS Pathogens. Certain beneficial gut bacteria, however, appeared to reduce the damage.

alt

AIDS 2014: Low Level Viral Load Does Not Raise Risk of HIV Treatment Failure

People with HIV who have a low-level viral load between 20 and 50 copies/mL were not more likely to experience virological failure of antiretroviral therapy (ART) compared with those who consistently maintained viral suppression below 20 copies/mL, according to research presented at the 20th International AIDS Conference in Melbourne.

alt